Association between paraoxonase 1 activity and severity of coronary artery disease in patients with acute coronary syndromes

Acta Cardiologica

Volumn 63, Issue 3, 2008, Pages 361-367

  Şentürk, Tunay ^a,b   Sarandöl, Emre ^b   Güllülü, Sümeyye ^a   Erdinç, Selda ^b   Özdemir, Bülent ^a   Baran, Ibrahim ^a   Aydinlar, Ali ^a  

^a Departments of Cardiology   (Canada)

^b ULUDAG UNIVERSITY   (Turkey)

Author keywords

Acute coronary syndrome; Arylesterase; Coronary artery disease; Paraoxonase

Indexed keywords

ACETYLSALICYLIC ACID; ARYLDIALKYLPHOSPHATASE 1; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRATE;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; ELECTROCARDIOGRAM; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; SPECTROPHOTOMETRY; ST SEGMENT ELEVATION; UNSTABLE ANGINA PECTORIS;

ARYLDIALKYLPHOSPHATASE; BIOLOGICAL MARKERS; CORONARY ANGIOGRAPHY; CORONARY DISEASE; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROGNOSIS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SYNDROME;

EID: 46449098142     PISSN: 00015385     EISSN: None     Source Type: Journal    
DOI: 10.2143/AC.63.3.1020314     Document Type: Article

References (32)

1. Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipopro-tein. FEBS Lett 1991; 286: 152-4.
2. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions: a possible peroxidative role for paraoxonase. J Clin Invest 1998; 101: 1581-90.
3. Aviram M. Does paraoxonase play a role in susceptibility to cardiovascular disease? Mol Med Today 1999; 5: 381-6.
4. Li LH, Liu DP, Liang CC. Paraoxonase gene polymorphism, oxidative stress and disease. J Mol Med 2003; 81: 766-79.
5. La Du BN, Aviram M, Billecke S, Navab M, Primo-Parmo S, Sorenson RC, Standiford TJ. On the physiological role(s) of the paraoxonases. Chem Biol Interact 1999; 119-120: 379-88.
6. Tward A, Xia YR, Wang XP, Shi YS, Park C, Castellani LW, Lusis AJ, Shih DM. Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation 2002; 106: 484-90.
7. Oda MN, Bielicki JK, Ho TT, Berger T, Rubin EM, Forte TM. Paraoxonase 1 overexpression in mice and its effect on high-density lipoproteins. Biochem Biophys Res Commun 2002; 290: 921-7.
8. Inoue M, Suehiro T, Nakamura T, Ikeda Y, Kumon Y, Hashimoto K. Serum arylesterase/diazoxonase activity and genetic polymorphisms in patients with type 2 diabetes. Metabolism 2000; 49: 1400-5.
9. Shih DM, Gu L, Xia YR, Navab M, Li WF, Hama S. Castellani LW, Furlong CE, Costa LG, Fogelman AM, Lusis AJ. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 1998; 394: 284-7.
10. Ayub A, Mackness MI. Arrol S, Mackness B. Patel J. Durrington PN. Serum paraoxonase after myocardial Infarction. Arteriosder Thromb Vasc Biol 1999; 19: 330-5.
11. Kabaroglu C, Mutaf I, Boydak B, Ozmen D, Habif S, Erdener D, Parildar Z, Bayindir O. Association between serum paraoxonase activity and oxidative stress in acute coronary syndromes. Acta Cardiol 2004; 59: 606-11.
12. Mackness B, Mackness MI, Arrol S. Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus. Atherosclerosis 1998; 139: 341-9.
13. DeWood MA, Spores J, Notske R, Mouser LT, Burroughs R, Golden MS, Lang HT. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980; 303: 897-902.
14. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings: TIMI Study Group. N Engl J Med 1985; 312: 932-6.
15. DeWood MA, Stifter WF, Simpson CS, Spores J, Eugster GS, Judge TP, Hinnen ML. Coronary arteriographic findings soon after non-Q-wave myocardial infarction. N Engl J Med 1986; 315: 417-23.
16. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined - a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000; 36: 959-69.
17. Braunwald E. Unstable angina: A classification. Circulation 1989; 80: 410-4.
18. Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol 1983; 51: 606.
19. Eckerson HW, Wyte MC, La Du BN. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet 1983; 35: 1126-38.
20. Haagen L, Brock A. A new automated method for pheno-typing arylesterase (E.C.3.1.1.2.) based upon inhibition of enzymatic hydrolysis of 4-nitrophenyl acetate by phenyl acetate. Eur J Clin Chem Clin Biochem 1992; 30: 391-5.
21. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
22. Azarsiz E, Kayikcioglu M, Payzin S, Yildirim Sozmen E. PON1 activities and oxidative markers of LDL in patients with angiographically proven coronary artery disease. Int J Cardiol 2003; 91: 43-51.
23. Mackness B, Davies GK, Turkie W, Lee E, Roberts DH, Hill E, Roberts C, Durrington PN, Mackness MI. Paraox-onase status in coronary heart disease. Are activity and concentration more important than genotype? Arterioscler Thromb Vasc Biol 2001; 21: 1451-7.
24. Serdar Z, Asian K, Dirican M, Sarandol E, Yesilbursa D, Serdar A. Lipid and protein oxidation and antioxidant status in patients with angiographically proven coronary artery disease. Clin Biochem 2006; 39: 794-803.
25. Graner M, James RW, Kahri J, Nieminen MS, Syvanne M, Taskinen MR. Association of paraoxonase-1 activity and concentration with angiographic severity and extent of coronary artery disease. J Am Coll Cardiol 2006; 47: 2429-35.
26. Rahmani M, Raiszadeh F, Allahverdian S, Kiaii S, Navab M, Azizi F. Coronary artery disease is associated with the ratio of apolipoprotein B, but not with paraoxonase enzyme activity in Iranian subjects. Atherosclerosis 2002; 162: 381-9.
27. Gur M, Asian M, Yildiz A, Demirbag R, Yilmaz R, Selek S, Erel O, Ozdogru I. Paraoxonase and arylesterase activities in coronary artery disease. Eur J Clin Invest 2006; 36: 779-87.
28. Navab M, Hama-Levy S, Van Lenten BJ, Fonarow GC, Cardinez CJ, Castellani LW, Brennan ML, Lusis AJ, Fogelman AM, La Du BN. Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio. J Clin Invest 1997; 99: 2005-19.
29. Mackness MI. 'A'-esterases: enzymes looking for a role? Biochem Pharmacol, 1989; 38: 385-90.
30. Mackness MI, Harty D, Bhatnagar D, Winocour PH, Arrol S, Ishola M, Durrington PN. Serum paraoxonase activity in familial hypercholesterolemia and insulin-dependent diabetes mellitus. Atherosclerosis 1991; 86: 193-8.
31. Sarkar PD, TM Shivaprakash, Madhusudhan B. Association between paraoxonase activity and lipid levels in patients with premature coronary artery disease. Clin Chimica Acta 2006; 373: 77-81.
32. Forrester JS. Role of plaque rupture in acute coronary syndromes. Am J Cardiol 2000; 86: 15J-23J.